BAY x 1005可减轻载脂蛋白E/低密度脂蛋白受体双敲除小鼠的动脉粥样硬化。
BAY x 1005 attenuates atherosclerosis in apoE/LDLR - double knockout mice.
作者信息
Jawień J, Gajda M, Olszanecki R, Korbut R
机构信息
Chair of Pharmacology, Jagiellonian University School of Medicine, Cracow, Poland.
出版信息
J Physiol Pharmacol. 2007 Sep;58(3):583-8.
Recently, we have shown that MK-886 - an inhibitor of five lipoxygenase activating protein (FLAP) inhibits atherosclerosis in apolipoprotein E / LDL receptor - double knockout mice. We, therefore, wanted to find out if other FLAP inhibitor - BAYx1005 given at a dose of 1.88 mg per 100 mg of body weight per day during 16 weeks, could also attenuate atherogenesis. In apoE/LDLR - DKO mouse model BAYx1005 inhibited atherogenesis, measured both by "en face" method (23.84 +/- 2.7% vs. 15.16 +/- 1.4%) and "cross-section" method (497236 +/- 31516 microm(2) vs. 278107 +/- 21824 microm(2)). This is the first report that shows the effect of BAYx1005 on atherogenesis in gene-targeted mice.
最近，我们已经表明，MK-886——一种5-脂氧合酶激活蛋白（FLAP）抑制剂，可抑制载脂蛋白E/低密度脂蛋白受体双敲除小鼠的动脉粥样硬化。因此，我们想弄清楚，在16周内每天以每100毫克体重1.88毫克的剂量给予另一种FLAP抑制剂——BAYx1005，是否也能减轻动脉粥样硬化的发生。在载脂蛋白E/低密度脂蛋白受体双敲除（apoE/LDLR-DKO）小鼠模型中，BAYx1005抑制了动脉粥样硬化的发生，这通过“正面”方法（23.84±2.7%对15.16±1.4%）和“横截面”方法（497236±31516平方微米对278107±21824平方微米）来衡量。这是第一份显示BAYx1005对基因靶向小鼠动脉粥样硬化发生影响的报告。
Zotero 插件